USPTO serial 98638778
PRINTBIO
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEASER, ANDREW C
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with PRINTBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $749*
Plus Government fees of $900
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Surfside, FL, US
Surfside, FL, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jared L. DuJack
Jared L. DuJack Schmeiser, Olsen & Watts, LLP22 Century Hill Drive, Suite 302Latham, NY 12110United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Collagen for scientific and research use | ACTIVE | — |
| 003 | Collagen preparations for cosmetic purposes | ACTIVE | — |
| 005 | Bioprinted organs comprising primarily living tissue for medical use; Bioprinted organs, namely, ears comprising primarily living tissue for medical use; Bioprinted organs, namely, livers comprising primarily living tissue for medical use; Bioprinted organs, namely, kidneys comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of ears comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of livers comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of kidneys comprising primarily living tissue for medical use; Autologous bioprinted organs comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, ears comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, livers comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, kidneys comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of ears comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of livers comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of kidneys comprising primarily living tissue for medical use; Bioprinted structures for organs comprising primarily living tissue for medical use; Autologous bioprinted structures for organs comprising primarily living tissue for medical use; Ink for 3D bioprinters comprising primarily living cells or other biological materials for medical purposes; Implantable protective shells comprising primarily living tissue; Implantable structural support devices comprising primarily living tissue; Implantable bioprinted exoskeletons comprising primarily living tissue; Implantable 3D bioprinted exoskeletons comprising primarily living tissue; Bioprinted surgical mesh comprising primarily living tissue; Bioresorbable surgical mesh comprising primarily living tissue; Bioprinted bioresorbable surgical mesh comprising primarily living tissue; Collagen for medical purposes; Collagen for medical purposes, namely, wound healing | ACTIVE | — |
| 007 | 3D bioprinters; 6-axis 3D bioprinters | ACTIVE | — |
| 010 | Implants and mesh made of synthetic materials for use in soft tissue repair or the reconstruction of soft tissue deficiencies; Implantable protective shells composed of synthetic material; Implantable structural support devices composed of synthetic material; Bioprinted organs comprising primarily synthetic material for medical use; Bioprinted organs, namely, ears comprising primarily synthetic material for medical use; Bioprinted organs, namely, livers comprising primarily synthetic material for medical use; Bioprinted organs, namely, kidneys comprising primarily synthetic material for medical use; Bioprinted organs, namely, portions of ears comprising primarily synthetic material for medical use; Bioprinted organs, namely, portions of livers comprising primarily synthetic material for medical use; Bioprinted organs, namely, portions of kidneys comprising primarily synthetic material for medical use; Autologous bioprinted organs comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, ears comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, livers comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, kidneys comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of ears comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of livers comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of kidneys comprising primarily synthetic material for medical use; Bioprinted structures for organs comprising primarily synthetic material for medical use; Autologous bioprinted structures for organs comprising primarily synthetic material for medical use; Ink for 3D bioprinters comprising primarily synthetic material or other materials for medical purposes; Implantable protective shells comprising primarily synthetic material; Implantable structural support devices comprising primarily synthetic material; Implantable bioprinted exoskeletons comprising primarily synthetic material; Implantable 3D bioprinted exoskeletons comprising primarily synthetic material; Bioprinted surgical mesh comprising primarily synthetic material; Bioresorbable surgical mesh comprising primarily synthetic material; Bioprinted bioresorbable surgical mesh comprising primarily synthetic material | ACTIVE | — |
| 044 | Medical services, namely, organ replacement therapy; Medical services, namely, organ replacement therapy using 3D bioprinting; Medical services, namely, organ replacement therapy using autologous bioprinting; Medical services, namely, on demand organ replacement therapy; Medical services, namely, on demand organ replacement therapy using 3D bioprinting; Medical services, namely, on demand organ replacement therapy using autologous bioprinting | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PrintBio, Inc.
- Other trademarks owned by PrintBio, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 007
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named PRINTBIO
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 19, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 24, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 24, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 18, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 28, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 27, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 27, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 27, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 2, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Dec 2, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Sep 2, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 2, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 2, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 21, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 21, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2025 | ALIE | ASSIGNED TO LIE | — |
| Aug 8, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 8, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| May 8, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Feb 8, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 31, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 9, 2024 | NWAP | NEW APPLICATION ENTERED | — |